Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence.

Abstract

PURPOSE OF THE REVIEW:

Recently introduced Gallium-68 labeled PSMA-ligands such as HBED-CC (68Ga-PSMA) have shown promise for unmet diagnostic needs in prostate cancer.

RECENT FINDINGS:

68Ga-PSMA has demonstrated improved detection rates and specificity for prostate cancer compared to standard imaging approaches. In the setting of primary disease, 68Ga-PSMA appears to preferentially identify treatment-relevant intermediate and high-risk prostate cancer. There is also a growing evidence that 68Ga-PSMA positron emission tomography (PET) outperforms alternative conventional imaging methods including choline-based radiotracers for the localization of disease sites at biochemical recurrence, particularly at lower prostate-specific antigen (PSA) levels (< 1 ng/mL). However, the majority of published work lacks rigorous verification of imaging results. 68Ga-PSMA offers significant promise for both, primary disease and biochemically recurrent prostate cancer. The evidence base to support 68Ga-PSMA is however still underdeveloped, and more rigorous studies substantiating efficacy are needed.

• Authors: Jason Bailey, Morand Piert
• Journal: Current urology reports (Curr Urol Rep) Vol. 18 Issue 11 Pg. 84 (Sep 09 2017) ISSN: 1534-6285 [Electronic] United States
• PMID: 28889366 (Publication Type: Journal Article, Review)

Chemical References

• Radiopharmaceuticals
• N,N'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N'-diacetic acid
• Edetic Acid
• Prostate-Specific Antigen

Topics

• Edetic Acid (analogs & derivatives)
• Humans
• Male
• Neoplasm Recurrence, Local (diagnostic imaging, pathology)
• Neoplasm Staging (methods)
• Positron Emission Tomography Computed Tomography (methods)
• Positron-Emission Tomography (methods)
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (diagnostic imaging, pathology)
• Radiopharmaceuticals